- The stock price of BIOLASE Inc (NASDAQ: BIOL) increased by over 40% pre-market today. This is why it happened.
The stock price of BIOLASE Inc (NASDAQ: BIOL) increased by over 40% pre-market today. Investors are responding positively to BIOLASE announcing its receipt of written notification from the Listing Qualification Department of The NASDAQ Stock Market granting BIOLASE’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the bid price rule).
Now BIOLASE has until May 23, 2022 to regain compliance with the bid price rule. And Nasdaq’s extension notice has no immediate effect on the continued listing status of BIOLASE’s common stock, which remains listed on The NASDAQ Capital Market.
If at any time until May 23, 2022, the bid price for BIOLASE’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive trading days, BIOLASE will regain compliance with the bid price rule, and the matter will be closed. And BIOLASE will continue to monitor the bid price for its common stock and consider various available options if BIOLASE’s common stock does not trade at a level that is likely to regain compliance with the bid price rule. There can be no assurance that BIOLASE will regain compliance with the bid price rule or maintain compliance with any of the other Nasdaq continued listing requirements during this extended compliance period.
Separately, BIOLASE had announced that on November 18, 2021, it entered into an amendment to its senior secured term loan with SWK Funding LLC — which among other improvements extended the maturity of the loan to May 31, 2025 and reduced the effective interest rate on the loan by 200 basis points. SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a Dallas, Texas-based healthcare focused investment firm.
“The 180-day extension from NASDAQ gives us more time to demonstrate the success of our growth strategy, which has delivered stellar results over the past three quarters, and for the financial community to acknowledge and value the opportunity we have ahead. Additionally, the amendment to our loan with SWK demonstrates its belief in our ability to deliver continued strong growth as new customers adopt our market-leading dental lasers.”
— John Beaver, President and Chief Executive Officer of BIOLASE
“We remain impressed with BIOLASE’s continued operating traction as evidenced by increasing market acceptance of its dental lasers. The strong operating results combined with the company’s healthy balance sheet positions BIOLASE to achieve its growth plans driven by continued new customer adoption of their lasers, which provide a greater standard of care for dental procedures and a safer environment for dental practitioners and their patients.”
— Winston Black, Chief Executive Officer of SWK Holdings
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.